A young Romanian researcher who had graduated medicine at Yale University and worked at Johns Hopkins in the USA has returned home to join a medical team set to find a natural cure for cancer.
Raul Pătrașcu has lived in the U.S. for six years and now he came back to Romania, precisely, in Timisoara, to use his expertize at Oncogen, the Center of Genetic and Cellular Therapies for Cancer Treatment, one of the modern such centers in Europe.
Why has he chosen to return to a country, which, apart from being his mother country, is also a state where medicine and research are poorly ranked in terms of financial allotments? Romania is in second-to-last place on EU funds allotted to research. “It’s easy to do research in the U.S, but satisfaction is higher in Romania”, Raul Pătrașcu said, as quoted by Digi24.
After practicing preclinical medicine and chemistry in the U.S., after publishing a paper on pancreatic cancer at the renowned cancer research center of Johns Hopkins and after even working on Wall Street for a year, he has now joined Oncongen, a new research center based in Timisoara, which has the goal to modify the immune system so that it should recognize and destroy any malign tumor.
According to the young researcher, the Oncogen center has all equipment needed to do research at high level, and the same research infrastructure has started to be implemented nationwide, in Cluj, Bucharest or Iasi.
The center coordinator Virgil Păunescu says that there have been more youngsters who studied abroad and who are coming back to work in Romania, and that talks are under way to convince four advanced researchers to come to Timisoara to join the team which is fighting cancer. Over 50 specialists are working now at Oncogen.
The center is part of the Timisoara County Hospital structure. Almost 10 million euros have been invested here, mostly European funds, during 2010-2015.
According to the National Institute of Statistics, in 2016, Romania allotted RON 3.47 billion for research, meaning 0.48% of the national budget, which means our country is second to last place in the EU, where the average is over 2%.